Nanobiotix receives approval from ANSM

NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has announced that its lead compound NBTXR3 has received authorisation from the French Medicine Agency, ANSM,(1) to start a clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer), at the Institut Curie, Paris, France, a French leading cancer treatment centre. This represents a second indication for NBTXR3 which is also in clinical trials for soft tissue sarcoma.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news